EP
PRLD icon

Essential Partners’s Prelude Therapeutics PRLD Stock Holding History

Essential Partners’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17
Closed -$24 – 2885
2025
Q3 		$24 Sell
17
-70
-80% -$70 ﹤0.01% 2626
2025
Q2 		$70 Buy
+87
New +$75 ﹤0.01% 2113

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's PRLD Position: Q4 2025 in Review

Essential Partners sold out of Prelude Therapeutics (PRLD) in Q4 2025, closing a stake of 17 shares — an estimated $24 sold.

Essential Partners first reported a position in PRLD in Q2 2025 and held it in 2 quarters. The position peaked at $70 in Q2 2025. 48 funds tracked by Wall St. Rank hold PRLD as of Q4 2025.

  • Essential Partners reported no remaining Prelude Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Essential Partners sold 17 Prelude Therapeutics shares in Q4 2025, an estimated $24.
  • Essential Partners first reported a position in Prelude Therapeutics in Q2 2025 and held it in 2 quarters.
  • Essential Partners's Prelude Therapeutics position peaked at $70 in Q2 2025.
  • 48 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2025.

Based on Essential Partners's 13F filing for Q4 2025, filed 21 May 2026.